(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate

• ChemBase ID: 497
• Molecular Formular: C46H62N4O11
• Molecular Mass: 847.00468
• Monoisotopic Mass: 846.44150882
• SMILES: C12(CCN(CC1)CC(C)C)N=C1c3c4c(c(c5c3C(=O)[C@@](O/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H](O)[C@H](/C=C/C=C(\C(=O)NC(=C1N2)C4=O)/C)C)C)O)C)OC(=O)C)C)OC)(O5)C)C)O
• Canonical SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(NC4=C(C(=O)c2c(c3C)O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]1C)OC(=O)C)C)O)C)O)C)/C)CCN(CC5)CC(C)C
• InChI: InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
• InChIKey: ATEBXHFBFRCZMA-VXTBVIBXSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1(31),2,4,9,19,21,25,29-octaen-13-yl acetate
• IUPAC Traditional name: @rifabutin
• Brand Name: Ansamycin; Alfacid; Mycobutin
• Synonyms: Rifabutinum [Latin]; Rifabutine [French]; Rifabutina [Spanish]; RBT; Antibiotic LM 427; Ansatipine; Ansatipin; Rifabutin; Mycobutin; Ansamycin; LM 427

Database IDs

• CAS Number: 72559-06-9
• PubChem SID: 160963960; 46506468
• PubChem CID: 6323490

CALCULATED PROPERTIES

JChem

• Acid pKa: 7.9468403
• H Acceptors: 13
• H Donor: 5
• LogD (pH = 5.5): 2.153332
• LogD (pH = 7.4): 3.853648
• Log P: 4.1864443
• Molar Refractivity: 232.6445 cm^3
• Polarizability: 88.737564 Å^3
• Polar Surface Area: 205.55 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 4.25
• LOG S: -4.7
• Solubility (Water): 1.70e-02 g/l

PROPERTIES

Physical Property

• Solubility: Minimally soluble (0.19 mg/mL)
• Hydrophobicity(logP): 4.1

Safety Information

• Storage Condition: -20°C

Product Information

• Salt Data: Free Base

DETAILS

DrugBank - DB00615

• Drug Groups: approved
• Description: A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. [PubChem]
• Indication: For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
• Pharmacology: Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifabutin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.
• Toxicity: LD₅₀ = 4.8 g/kg (mouse, male)
• Affected Organisms: Enteric bacteria and other eubacteria
• Biotransformation: Hepatic. Of the five metabolites that have been identified, 25-O-desacetyl and 31-hydroxy are the most predominant. The former metabolite has an activity equal to the parent drug and contributes up to 10% to the total antimicrobial activity.
• Absorption: Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.
• Half Life: 45 (± 17) hours
• Protein Binding: 85%
• Elimination: A mass-balance study in three healthy adult volunteers with 14C-labeled rifabutin showed that 53% of the oral dose was excreted in the urine, primarily as metabolites. About 30% of the dose is excreted in the feces.
• Clearance: * 0.69 +/- 0.32 L/hr/kg
• External Links: Wikipedia; RxList; Drugs.com

Selleck Chemicals - S1741

Research Area: Infection
Biological Activity:
Rifabutin(Mycobutin) is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties. Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. [1, 2]

REFERENCES

• http://en.wikipedia.org/wiki/Rifabutin